Kisqali vs Lynparza
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Kisqali | US Lynparza | |
|---|---|---|
| Generic name | ribociclib | olaparib |
| Drug class | CDK4/6 Inhibitor | PARP Inhibitor |
| Treats | HR-positive, HER2-negative breast cancer | Ovarian, breast, prostate, and pancreatic cancers |
| Category | Oncology | Oncology |
| Manufacturer | Novartis | AstraZeneca |
| Year approved | 2017 | 2014 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $80M | — |
| Common side effects | Low white blood cells, Nausea, Fatigue, Heart rhythm changes (QT) | Nausea, Fatigue, Low blood counts, Risk of blood cancers (MDS/AML) |
Frequently asked questions
Is Kisqali or Lynparza better?
Neither is universally "better." Kisqali (ribociclib) and Lynparza (olaparib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Kisqali and Lynparza?
Kisqali is a CDK4/6 Inhibitor made by Novartis, while Lynparza is a PARP Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Kisqali has the larger estimated TV advertising budget of the two.